Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16742442 | 1.00 | ENPP2 (0.55) | ENPP2CA1CA2FABP4HDAC1 | |
| SCHEMBL30426169 | 1.00 | ENPP2 (0.55) | ENPP2CA1CA2FABP4HDAC1 | |
| Hydrochloric Acid SCHEMBL18044813 | 0.99 | ENPP2 (0.54) | ENPP2CA1CA2FABP4HDAC1 | |
| Hydrochloric Acid SCHEMBL18044814 | 0.99 | ENPP2 (0.54) | ENPP2CA1CA2FABP4HDAC1 | |
| SCHEMBL8381090 | 0.92 | CA1 (0.49) | ENPP2CA1CA2FABP4HDAC1 | |
| SCHEMBL11017941 | 0.92 | CA1 (0.49) | ENPP2CA1CA2FABP4HDAC1 | |
| SCHEMBL16750316 | 0.89 | ENPP2 (0.50) | ENPP2CA1CA2FABP4HDAC1 | |
| SCHEMBL18044817 | 0.87 | ENPP2 (0.51) | ENPP2FABP4HDAC1HDAC6HDAC10 | |
| SCHEMBL18070807 | 0.86 | ENPP2 (0.42) | ENPP2FABP4TBXA2RPTGDR2 | |
| Hydrochloric Acid SCHEMBL18044819 | 0.85 | ENPP2 (0.41) | ENPP2FABP4TBXA2RPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458627-B2 | Autotaxin inhibitors and uses thereof | DF 2024 IP ACQUISITION, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| CN-116059203-A | Autotaxin inhibitors and uses thereof | 赛博治疗有限责任公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4026549-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | Sabre Therapeutics LLC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3302490-B1 | AUTOTAXIN INHIBITORS AND USES THEREOF | SABRE THERAPEUTICS LLC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20200215034-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | INSOLVENCY SERVICES GROUP, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10632104-B2 | Autotaxin inhibitors and uses thereof | SABRE THERAPEUTICS LLC (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180162859-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ATXCO, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180162859-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ATXCO, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180162859-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ATXCO, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180147185-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-9926318-B2 | Tetracyclic autotaxin inhibitors | PHARMAKEA, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| WO-2016191427-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| EP-3071569-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | Pharmakea Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | DF 2024 IP ACQUISITION, LLC | 2016-09-15 | — | — | US | disclosed |
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | DF 2024 IP ACQUISITION, LLC | 2016-09-15 | — | — | US | disclosed |
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | DF 2024 IP ACQUISITION, LLC | 2016-09-15 | — | — | US | disclosed |
| US-9051320-B1 | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor | PHARMAKEA, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051320-B1 | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor | PHARMAKEA, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2015077502-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077502-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147185-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, RNASE1 | ENPP2 1/4885CA1 2303/4885CA2 3009/4885 |
| US-20180162859-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, UACA | ENPP2 1/4885CA1 1161/4885CA2 1375/4885 |
| US-10632104-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | ENPP2 1/4885CA1 2303/4885CA2 3009/4885 |
| US-20200215034-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, RNASE1 | ENPP2 1/4885CA1 2303/4885CA2 3009/4885 |
| US-12458627-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | ENPP2 1/4885CA1 2303/4885CA2 3009/4885 |
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, UACA | ENPP2 1/4885CA1 1161/4885CA2 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.